Valuation : Marvel Biosciences Corp.

Market Cap 9.45M 6.86M 5.9M 5.55M 5.07M 651M 9.5M 65.78M 25.45M 333M 25.77M 25.21M 1.06B P/E 2024
-2.91x
P/E 2025 -3.74x
Enterprise Value 11.64M 8.45M 7.26M 6.83M 6.23M 801M 11.7M 80.95M 31.32M 409M 31.72M 31.02M 1.3B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.69%
Yield 2024 *
-
Yield 2025 -
1 day-6.67%
1 week-9.68%
Current month-6.67%
1 month-15.15%
3 months-30.00%
Current year+3.70%
1 week 0.13
Extreme 0.13
0.16
1 month 0.13
Extreme 0.13
0.18
Current year 0.12
Extreme 0.115
0.25
1 year 0.12
Extreme 0.115
0.26
3 years 0.01
Extreme 0.01
0.4
5 years 0.01
Extreme 0.01
0.4
10 years 0.01
Extreme 0.01
0.4
Manager TitleAgeSince
Chief Executive Officer - 2021-06-13
Director of Finance/CFO 37 2022-01-31
President 54 2021-06-13
Director TitleAgeSince
Chairman - -
Director/Board Member 54 2021-06-13
Director/Board Member 57 2021-06-13
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Option

Director

16,667 0.0264%
9/1/26 Tax

Director

16,667 0.0264%
9/1/26 Tax

Director

16,667 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
-6.67%-9.68%-44.00%+100.00% 6.41M
-0.97%-3.77%-2.49%+14.92% 48.01B
-1.29%-1.22%+404.92%+545.45% 44.44B
-3.20%+0.33%+38.11%+21.39% 42.67B
-1.89%-2.00%+1.45%+82.46% 39.96B
-1.72%-2.61%+13.09%+42.33% 32.75B
-0.17%+3.78% - - 17.74B
-0.07%+1.32%+20.08%+117.95% 16.49B
-0.20%-2.34%+11.13%+31.19% 14.38B
-2.68%-0.56%+73.31%+40.56% 13.4B
Average -1.88%-1.40%+57.29%+110.70% 26.98B
Weighted average by Cap. -1.53%-1.05%+85.12%+132.83%

Financials

2024 2025
Net sales - -
Net income -1.65M -1.2M -1.03M -969K -884K -114M -1.66M -11.48M -4.44M -58.04M -4.5M -4.4M -185M -2.21M -1.61M -1.38M -1.3M -1.19M -152M -2.22M -15.39M -5.95M -77.79M -6.03M -5.9M -248M
Net Debt 1.36M 990K 851K 801K 731K 93.88M 1.37M 9.49M 3.67M 47.99M 3.72M 3.64M 153M 2.18M 1.58M 1.36M 1.28M 1.17M 150M 2.19M 15.17M 5.87M 76.72M 5.95M 5.82M 244M
Logo Marvel Biosciences Corp.
Marvel Biosciences Corp. is a Canada-based pre-clinical-stage pharmaceutical development biotechnology company. The Company develops new synthetic chemical derivatives of the original approved drug for the new disease indication. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs that inhibit the A2a adenosine receptor with application to neurological diseases (depression and anxiety, Alzheimer's, attention deficit hyperactivity disorder (ADHD)), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The Company's lead compound, MB-204, is a fluorinated derivative of Istradefylline. The Company is engaged in developing MB-204 for diseases other than Parkinson's disease, specifically depression, Alzheimer’s Disease and liver fibrosis due to non-alcoholic steatohepatitis (NASH). Its wholly owned subsidiary is Marvel Biotechnology Inc.
Employees
-
Date Price Change Volume
26-09-08 $0.1400 -6.67% 149,374
26-09-04 $0.1500 0.00% 16,793
26-09-03 $0.1500 0.00% 43,596
26-09-02 $0.1500 -3.23% 17,001
26-09-01 $0.1550 +3.33% 36,014
  1. Stock Market
  2. Stocks
  3. MRVL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!